Fosun International Ltd purchased a new position in Agile Therapeutics Inc (NASDAQ:AGRX) during the third quarter, HoldingsChannel reports. The fund purchased 466,302 shares of the specialty pharmaceutical company’s stock, valued at approximately $180,000.
Separately, Renaissance Technologies LLC grew its holdings in Agile Therapeutics by 76.3% during the 2nd quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after buying an additional 343,290 shares during the last quarter. Hedge funds and other institutional investors own 52.81% of the company’s stock.
A number of equities research analysts have commented on the company. HC Wainwright set a $4.00 target price on Agile Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 9th. ValuEngine upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 3rd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $4.00.
Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. Equities research analysts forecast that Agile Therapeutics Inc will post -0.59 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “466,302 Shares in Agile Therapeutics Inc (AGRX) Purchased by Fosun International Ltd” was published by WKRB News and is the property of of WKRB News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.wkrb13.com/2018/11/23/466302-shares-in-agile-therapeutics-inc-agrx-purchased-by-fosun-international-ltd.html.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Want to see what other hedge funds are holding AGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agile Therapeutics Inc (NASDAQ:AGRX).
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.